



NDA 205572/S-004

**SUPPLEMENT APPROVAL**

Fresenius Kabi USA, LLC  
Attention: John McNally  
Senior Regulatory Specialist  
Three Corporate Drive  
Lake Zurich, IL 60047

Dear Mr. McNally:

Please refer to your New Drug Application (NDA) submitted under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Moxifloxacin Injection, 40 mg/250 mL.

We also refer to our letter dated July 10, 2018, notifying you, under Section 505(o)(4) of the FDCA, of new safety information required to be included in the labeling for the systemic fluoroquinolone class of antibacterial drugs. This information pertains to the risk of psychiatric adverse reactions and hypoglycemic coma which are included in the **WARNINGS AND PRECAUTIONS** section.

This supplemental new drug application provides for revisions to the **WARNINGS AND PRECAUTIONS** section (5) for Moxifloxacin Injection, consistent with our July 10, 2018, safety labeling change notification letter.

**APPROVAL & LABELING**

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert, Medication Guide), with the addition of any labeling changes in pending "Changes Being Effectuated" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Susmita Samanta, Safety Regulatory Project Manager, at (301) 796-0803.

Sincerely,

*{See appended electronic signature page}*

Joseph G. Toerner, M.D., M.P.H.  
Deputy Director for Safety  
Division of Anti-Infective Products  
Office of Antimicrobial Products  
Center for Drug Evaluation and Research

ENCLOSURE:  
Content of Labeling

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

JOSEPH G TOERNER  
10/18/2018